Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IN8bio Inc. Common Stock
INAB | US
1.55
USD-0.11
-6.63%
INAB | US
Loading StockChartView...
About IN8bio Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/03/2026
Close
1.55
Open
1.66
High
1.67
Low
1.50
IN8bio Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200 a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100 an allogeneic product candidate which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400 which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300 INB-410 and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics Inc. and changed its name to IN8bio Inc. in August 2020. IN8bio Inc. was incorporated in 2016 and is headquartered in New York New York.
View LessINAB | US
Risk
109.2
Sharpe
-0.92
Luna's Score
39/100
Recommendation
Sell
Luna says (INAB | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
150.8%1 month
109.2%3 months
103.0%6 months
98.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.23
Debt to equity
0.43
Debt to assets
0.26
Ent. to EBITDA
-1.15
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-30.63M
MarketCap
112.45M
MarketCap(USD)
112.45M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-180.45
Short ratio
0.44
Short perc.
0.61
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.61
Range1M
0.61
Range3M
1.38
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.48
Price X volume
140.09K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.15 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.23 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 103.02 | 72.80 | Riskier |
| Debt to Equity | 0.43 | -1.23 | Expensive |
| Debt to Assets | 0.26 | 0.25 | Par |
| Market Cap | 112.45M | 3.66B | Emerging |
